Amphetamine

Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19

Retrieved on: 
Monday, February 28, 2022

PHILADELPHIA, PA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued patent No. 11,253,490 covering the use of its proprietary investigational abuse-deterrent formulation of dextroamphetamine, ADAIR, for the treatment of cognitive impairment (sometimes referred to as “COVID brain fog”) associated with COVID-19.

Key Points: 
  • 11,253,490 covering the use of its proprietary investigational abuse-deterrent formulation of dextroamphetamine, ADAIR, for the treatment of cognitive impairment (sometimes referred to as COVID brain fog) associated with COVID-19.
  • The new U.S. patent covers a method of use for ADAIR for treating or alleviating symptoms of cognitive impairment in patients who have had a COVID-19 infection, with a base patent term extending until 2041.
  • New research suggests that there may be long-term neurologic consequences in many patients who survive COVID infections, including cognitive impairment and attention issues.
  • COVID brain fog refers to cognitive impairment experienced by patients who have recovered or are recovering from COVID-19.

Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, February 14, 2022

PHILADELPHIA, PA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the fiscal year ended December 31, 2021.

Key Points: 
  • Additionally, we continue to make progress with our second development program, ADMIR, and we expect to commence a first-in-human study this year.
  • Net loss was $9.3 million and $4.8 million for the fiscal years ended December 31, 2021 and 2020, respectively.
  • Research and development expenses were $5.2 million and $3.7 million for the fiscal years ended December 31, 2021, and 2020, respectively.
  • General and administrative expenses were $4.1 million and $1.2 million for the fiscal years ended December 31, 2021, and 2020, respectively.

Attention Deficit Hyperactivity Disorder (ADHD) Market Spotlight Report 2021: 10-year Disease Prevalence Forecast, and Licensing and Acquisition Deals, Drug-specific Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022

The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?"

Key Points: 
  • The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?"
  • This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The publisher estimates that in 2019, there were 179.8 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5-44 years worldwide, and forecasts that number to increase to 189.0 million prevalent cases by 2028.
  • Takeda leads industry sponsors with the highest overall number of clinical trials for ADHD, followed by Eli Lilly.

Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

Retrieved on: 
Thursday, January 20, 2022

PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that David Baker, President and Chief Executive Officer will present at the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 9:00 AM ET.

Key Points: 
  • As part of the virtual event, the Company will provide a brief presentation, followed by a moderated discussion and an interactive Q&A session.
  • In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event.
  • Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com .
  • Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA.

Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

Retrieved on: 
Tuesday, January 4, 2022

PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (Vallon or the Company), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the virtual H.C. Wainwright BioConnect Conference , taking place January 10-13, 2022.

Key Points: 
  • PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (Vallon or the Company), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the virtual H.C. Wainwright BioConnect Conference , taking place January 10-13, 2022.
  • Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA.
  • The Company is focused on the development of new medications to help patients with CNS disorders.
  • For more information about the company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter .

Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR

Retrieved on: 
Thursday, December 23, 2021

PHILADELPHIA, PA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that the last patient has completed their final visit in the pivotal SEAL intranasal abuse study evaluating ADAIR1, a proprietary abuse-deterrent formulation of immediate-release (IR) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.

Key Points: 
  • The SEAL study enrolled 55 subjects who successfully passed the qualification phase with a total of 53 completing the study.
  • The primary endpoint of the study is Emax Drug Liking, a standard abuse liability parameter typically used in human abuse liability studies.
  • The study was designed with 90% powering to show a statistically significant difference between snorted ADAIR after professional manipulation compared to snorted crushed dextroamphetamine.
  • We are thrilled to have completed the patient enrollment and treatment phase of our pivotal SEAL study, which represents a significant milestone for the Company.

Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

PHILADELPHIA, PA, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended September 30, 2021.

Key Points: 
  • We are pleased with the progress made over the course of the third quarter.
  • Patient enrollment remains ongoing with the final patient visit and completion of treatment expected in the first quarter of 2022 with topline results expected shortly thereafter.
  • Research and development expenses were $0.2 million and $0.7 million for the three months ended September 30, 2021 and 2020, respectively.
  • General and administrative expenses were $1.0 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively.

IQST – iQSTEL To Begin EVOSS Electric Motorcycle Manufacturing Next Week

Retrieved on: 
Thursday, November 11, 2021

New York, NY, Nov. 11, 2021 (GLOBE NEWSWIRE) -- iQSTEL, Inc. (OTCQX: IQST) today announced the manufacturing of its EVOSS electric motorcycles is scheduled to begin next week.

Key Points: 
  • New York, NY, Nov. 11, 2021 (GLOBE NEWSWIRE) -- iQSTEL, Inc. (OTCQX: IQST) today announced the manufacturing of its EVOSS electric motorcycles is scheduled to begin next week.
  • The first production run includes the EVOSS 250, 350 and 450 models equipped with 2-, 3-, and 4-Kw motors.
  • To see the EVOSS electric motorcycle, visit our YouTube Channel: https://www.youtube.com/channel/UCsaklYVEBqfDVOnDjZVYNxw
    The EVOSS electric motorcycle is a custom design with a max range up to 150 Km per battery charge, a max speed up to 90 Km/h, and a max torque of 140 N varying based on model.
  • Management is scheduled to present the EVOSS electric motorcycle forecast to our independent Board of Directors.

iQSTEL EVOSS Electric Motorcycle Manufacturing Schedule To Begin Next Week

Retrieved on: 
Thursday, November 11, 2021

NEW YORK, Nov. 11, 2021 /PRNewswire/ --iQSTEL, Inc. (OTCQX: IQST) today announced the manufacturing of its EVOSS electric motorcycles is scheduled to begin next week.

Key Points: 
  • NEW YORK, Nov. 11, 2021 /PRNewswire/ --iQSTEL, Inc. (OTCQX: IQST) today announced the manufacturing of its EVOSS electric motorcycles is scheduled to begin next week.
  • The first production run includes the EVOSS 250, 350 and 450 models equipped with 2, 3, and 4 Kw motors.
  • To see the EVOSS electric motorcycle, visit our You Tube Channel: https://www.youtube.com/channel/UCsaklYVEBqfDVOnDjZVYNxw
    The EVOSS electric motorcycle is a custom design with a max range up to 150 Km per battery charge, a max speed up to 90 Km/h, and a max torque of 140 N varying based on model.
  • Management is scheduled to present the EVOSS electric motorcycle forecast to our independent Board of Directors.

Fraud Alert & Public Safety Warning: Organized Fraud Ring Selling Fake or Non-Existent COVID-19 Vaccines and PPE Products

On August 6, 2021, Coriaty was arrested by the Monroe County Sheriffs Office in an alleged road rage incident.

Key Points: 
  • On August 6, 2021, Coriaty was arrested by the Monroe County Sheriffs Office in an alleged road rage incident.
  • A separate victim filed a Florida Bar complaint against Smith, accusing him of helping to facilitate fraud ( No.
  • According to the complaint, the victim never received the PPE they purchased nor did Coriaty return their tens of thousands of dollars.
  • Jerue received money from the proceeds of at least one PPE fraud, yet it is unknown why she was compensated.